Application of Fragment-Based Drug Discovery to Membrane Proteins: Identification of Ligands of the Integral Membrane Enzyme DsbB  by Früh, Virginie et al.
Chemistry & Biology
ArticleApplication of Fragment-Based Drug Discovery
to Membrane Proteins: Identification of Ligands
of the Integral Membrane Enzyme DsbB
Virginie Fru¨h,1 Yunpeng Zhou,2 Dan Chen,3 Caroline Loch,3 Eiso AB,3 Yelena N. Grinkova,4 Herman Verheij,5
Stephen G. Sligar,4 John H. Bushweller,2,6 and Gregg Siegal1,*
1Leiden Institute of Chemistry, Leiden University, Leiden 2300RA, The Netherlands
2Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA
3ZoBio BV, Leiden 2300RA, The Netherlands
4University of Illinois, 116 Morrill Hall, 505 S. Goodwin Avenue, Urbana, IL 61801, USA
5Pyxis Discovery, 2628XH Delft, The Netherlands
6Department of Chemistry, University of Virginia, Charlottesville, VA 22908, USA
*Correspondence: g.siegal@chem.leidenuniv.nl
DOI 10.1016/j.chembiol.2010.06.011SUMMARY
Membrane proteins are important pharmaceutical
targets, but they pose significant challenges for
fragment-based drug discovery approaches. Here,
we present the first successful use of biophysical
methods to screen for fragment ligands to an integral
membrane protein. The Escherichia coli inner mem-
brane protein DsbB was solubilized in detergent
micelles and lipid bilayer nanodiscs. The solubilized
protein was immobilized with retention of function-
ality and used to screen 1071 drug fragments for
binding using target immobilized NMR Screening.
Biochemical and biophysical validation of the eight
most potent hits revealed an IC50 range of 7–200 mM.
The ability to insert a broad array of membrane pro-
teins into nanodiscs, combined with the efficiency
of TINS, demonstrates the feasibility of finding frag-
ments targeting membrane proteins.
INTRODUCTION
With 60% of currently marketed drugs targeting membrane
proteins (Zheng et al., 2006), it is clear that finding small mole-
cules to modulate the function of such proteins is essential.
High throughput screening (HTS) methods have been successful
in identifying such compounds, but because the methods of
detection rely on functional assays, they are generally only
sensitive to submicromolar interactions. Such relatively tight
interactions are generally only observed for larger compounds
(300–500 Da). However, it has proved challenging to simulta-
neously optimize potency and absorption, distribution, metabo-
lism, and excretion (ADME) properties of these ‘‘lead-like’’ or
‘‘drug-like’’ compounds. Furthermore, such large compounds
inefficiently explore the binding sites of proteins (Carr et al.,
2005). Fragment-based drug discovery (FBDD) has become
a powerful complementary approach toHTS for generating novelChemistry & Biology 17, 88chemical modulators of pharmaceutical targets. FBDD screens
small libraries (1000–20,000 compounds) of so-called drug
‘‘fragments’’ that are often described by a ‘‘rule of threes’’
(Congreve et al., 2003) (Ro3, Mr <300 Da, cLogP <3, H-bond
donors <3, H-bond acceptors <3, number of rotatable bonds
<3 and TPSA (total polar surface area) <60 A˚2) for binding to
the target. Ro3-compliant compounds typically bind the target
with KD greater than 10 mM. In order to detect suchweak binding,
sensitive biophysical techniques are typically required, particu-
larly when the target is not an enzyme. Commonly used tech-
niques for detecting fragment binding include NMR, X-ray crys-
tallography, and surface plasmon resonance (SPR) (Siegal
et al., 2007).
Although biophysical methods have been successfully applied
to an array of soluble protein targets (Hajduk et al., 1997), they
have failed in one way or another when applied to membrane
proteins. There are two primary reasons for this failure: insuffi-
cient quantity of the target and problems related to the solubili-
zation media. Many biophysical methods require tens or even
hundreds of milligrams of purified, functional protein and most
membrane proteins are difficult to produce in these quantities.
However, recent advances have enabled the production of
low milligram quantities of a variety of MPs (Rasmussen et al.,
2007; Serrano-Vega et al., 2008; Dahmane et al., 2009). Mem-
brane proteins that can be produced in sufficient quantity must
then be solubilized in a surfactant while maintaining their func-
tional state, which is also often challenging. Finally, nonspecific
partitioning of fragments into the surfactant has been a severe
problem leading to high levels of false positives.
The use of detergent micelles to solubilize MPs has only met
limited success in retaining the native function of the protein
while at the same time the micelles often interfere with biophys-
ical assays. A possible solution to this bottleneck would be to
employ nondetergent media to functionally solubilize MPs. The
nanodisc (ND) has been developed as an alternative, surfac-
tant-free approach to solubilize MPs. NDs consist of a lipid
bilayer that is surrounded by an amphiphilic a-helical membrane
scaffold protein (MSP). A variety of proteins have been function-
ally solubilized in NDs (Nath et al., 2007; Katzen et al., 2008; Leitz
et al., 2006), which are much better mimics of the native1–891, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 881
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NDs for biophysical assays of ligand binding to MPs has yet to
be determined.
We have developed an NMR-based fragment screening
approach which has proven capable of overcoming many of
the challenges posed by membrane proteins (Fru¨h et al., 2008).
The approach, called target immobilized NMR screening (TINS)
(Vanwetswinkel et al., 2005), involves immobilizing a target
and a reference in two compartments of a dual-cell sample
holder (Marquardsen et al., 2006) and simultaneously injecting
mixtures of fragments in an automated process. For each
mixture, a 1D 1H NMR spectrum is recorded while fragment
binding to the target protein results in a decrease in peak ampli-
tude. The reference, which is selected for minimal specific small
molecule binding, serves to cancel out nonspecific binding of
fragments to protein surfaces. Hits can therefore be detected
by comparing spectra of the compounds recorded in the pres-
ence of the target to those recorded in the presence of the refer-
ence. By repeatedly using the same sample to screen the entire
fragment collection (>1000 compounds), typically only25 nmol
of protein is required, thus bringing manyMPs within the require-
ments for TINS. Furthermore, the reference system is expected
to account for nonspecific binding of fragments to the media in
which the membrane protein is solubilized.
We sought to apply TINS to a bona fide, integral membrane
pharmaceutical target that could be functionally solubilized in
detergent micelles and NDs. The inner membrane protein of
E. coli disulphide bond forming protein B (DsbB), and its homo-
logs in other Gram-negative bacteria, is an oxidoreductase that
is essential for protein disulfide bond formation in the periplasm
(Bardwell et al., 1993). Periplasmic DsbA functions as the cata-
lyst for protein disulfide bond formation and is reoxidized by
DsbB with concomitant reduction of bound ubiquinone or mena-
quinone. Since many bacterial virulence factors are secreted
proteins that require disulfide bonds for proper folding and func-
tion, the DsbA/DsbB system is a potential antimicrobial drug
target (Inaba and Ito, 2002; Stenson and Weiss, 2002; Jagu-
sztyn-Krynicka et al., 2009). DsbB is an ideal candidate to test
the TINS methodology since it can be produced in large quanti-
ties and solubilized in detergent micelles where it retains a robust
enzymatic activity which is easily assayed. In addition, a wealth
of biochemical data is available that describes the enzymatic
activity of the wild-type as well as numerous relevant mutants
(Jander et al., 1994; Bardwell et al., 1993; Regeimbal and Bard-
well, 2002; Kadokura et al., 2000). Finally, the 3D structures of
wild-type DsbB bound to its redox partner DsbA (Inaba et al.,
2006) and of a mutant representing an enzymatic intermediate
are available (Zhou et al., 2008). Selection of an appropriate
reference system is critical to insure the robust performance
of TINS. Our previous experience using the E. coli outer mem-
brane protein A (OmpA) transmembrane domain, which has
native structure under the same detergent micelle conditions
as DsbB (Arora et al., 2001), suggested that it had minimal small
molecule binding and would therefore serve as a good reference
(data not shown).
Here, we report the first complete screen of a fragment library
against an integral membrane protein. We have tested the appli-
cability of TINS for fragment screening using both micelle and
ND-solubilized protein. Hits from the screen have been validated882 Chemistry & Biology 17, 881–891, August 27, 2010 ª2010 Elseviand characterized with respect to mode of action using an
enzyme inhibition assay. Finally, the bindingmode of two classes
of inhibitors has been investigated by analysis of chemical shift
perturbations induced upon fragment binding to 15N-labeled
mutant DsbB.
RESULTS
DsbB Functional Immobilization and Enzymatic Activity
Wild-type DsbB (containing endogenous quinone) has previ-
ously been solubilized in DPC micelles, which we refer to as
DsbB/DPC, with retention of enzymatic function (Zhou et al.,
2008). We prepared protein similarly and immobilized it on a
Sepharose resin via a Schiff’s base intermediate. At the pH
selected (7.4), this reaction is relatively specific for the free
N terminus. A final concentration of approximately 100 mM
DsbB/DPC (nmol protein per milliliter settled bed volume) was
achieved with an overall yield of 50%. The functionality of
the immobilized enzyme was compared to nonimmobilized,
micelle-solubilized enzyme. The immobilized wild-type DsbB/
DPC retained 90% activity in comparison to the nonimmobilized
protein and the kcat of both forms of the protein was close to
values previously reported (Bader et al., 2000). The ready immo-
bilization with retention of enzymatic activity suggests that the
N terminus of DsbB is accessible in the micelle-solubilized
protein. We used the same approach to immobilize OmpA which
had also been solubilized in DPCmicelles (Arora et al., 2002) and
shown to be natively folded. We observed a similar yield of
OmpA immobilization. Since OmpA has no enzymatic activity,
we had to assume that its structure was not grossly perturbed
by the immobilization process. Independent experiments
showed that immobilized samples of DPC-solubilized DsbB
were stable for at least one month after storage at 4C (data
not shown).
We next trappedDPC-solubilized DsbB andOmpA inNDs. Gel
filtration analysis of our preparations revealed Stokes diameters
of 9.63, 9.68, and 9.52 nm for empty NDs (/ND), NDs with
embedded DsbB (DsbB/ND), and NDs with embedded OmpA
(OmpA/ND), in accordance with literature values (Civjan et al.,
2003) (see Supplemental Information available online). We deter-
mined a stoichiometry of 1 DsbB per ND by densitometric scan-
ning of gels of the preparations. The DsbB/ND was immobilized
using the same method as for DsbB/DPC with an overall yield of
75%. Nonimmobilized and immobilized DsbB/ND were assayed
for enzymatic activity for comparison to DsbB/DPC. Both DsbB/
ND preparations had a kcat that was somewhat greater than
the micelle-solubilized protein, indicating that they remained
completely functional (Supplemental Information). The increased
kcat for DsbB in NDs could possibly result from a more native
functionality of the enzyme in the lipid bilayer environment of
the ND.
Stability of the Immobilized Protein to Repeated Sample
Application Cycles
In a method such as TINS where a single sample of the target is
used to screen an entire compound collection, the integrity of the
immobilized protein is clearly critical. Soluble proteins are
routinely stable over more than 200 cycles of sample application
and washing (Vanwetswinkel et al., 2005). Solubilized MPser Ltd All rights reserved
Figure 1. Stability of the DsbB in Micelles
and NDs
The stability of DPC-solubilized (A) and ND-solubi-
lized (B) DsbB after multiple cycles of compound
application and washing was assessed by binding
of a known ligand, UQ1. Binding is displayed as
the average ratio of peak heights for the com-
pound in the presence of DsbB over that in the
presence of the reference (T/R ratio). The refer-
ence in (A) was DPC-solubilized OmpA and in (B)
/ND. Note the difference in vertical scale
between (A) and (B). See also Tables S1 and S2,
and Figure S1.
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protein itself, both of whichmust remain stable in order to ensure
proper ligand screening. Preliminary studies of DsbB/DPC and
OmpA/DPC clearly demonstrated that repeated cycles of
compound application and washing in the absence of added
detergent resulted in rapid degradation of DsbB activity (Fru¨h
et al., 2008). Therefore, deuterated DPC was included at a
minimum concentration of 5 mM (approximately three times
the critical micellar concentration) in the buffer used to wash
the compounds from the sample holder. The library, which con-
sisted of 1071 fragments at the time, was then screened in
mixtures that averaged approximately five compounds each in
the absence of DPC. Including control experiments designed
to monitor the physical integrity of the target and reference
samples, approximately 200 sample application/washing cycles
were performed. To monitor the integrity of the DsbB sample
during the screen, the binding of synthetic UQ1 was observed
(Figure 1A). In TINS, binding of a fragment is best described by
the T/R (target/reference) ratio, defined as the average ratio of
the amplitude of peaks in the presence of the target, DsbB, to
that in the presence of the reference, OmpA. It is clear from
Figure 1A that binding of UQ1 to DsbB/DPC remained relatively
constant throughout the screen which required 5.5 days to
complete.
Since it was not practical to rescreen the entire fragment
collection multiple times, we selected a subset of 20 compound
mixtures containing positive hits from the DsbB/DPC screen and
20 mixtures containing no positive hits from the DsbB/DPC
screen (a total of 183 compounds) to assess the suitability of
the ND system for ligand screening. The 40 mixes, along with
the control experiments used for DsbB/DPC, were applied
sequentially to the immobilized DsbB/ND using /ND as the
reference. We wanted to assess whether DsbB/ND and /ND
were stable in the absence of added phospholipid. As with
DsbB/DPC, we monitored the integrity of DsbB/ND, as deter-
mined by binding of a known ligand (UQ1), during multiple cycles
of compound application and washing in lipid-free buffers. The
T/R ratio for ligand binding to DsbB/ND versus /ND is shown
in Figure 1B. These data suggest a possible, initial small degra-
dation in binding behavior (although the variation is similar to that
seen in Figure 1A), after which the ligand binding capacity of
DsbB/ND remained constant. Alternatively, the small possible
decrease in ligand binding could be explained by the combina-
tion of a high-affinity binding mode, in which the ligand is ineffi-Chemistry & Biology 17, 88ciently removed by washing, and a low-affinity binding mode.
The constant T/R ratio during cycles 22 through 61 suggests
that both DsbB/ND and /ND remained intact.Target Immobilized NMR Screening of DsbB/DPC
The fragment collection was screened for binding to DsbB at
500 mM each, in 182 mixtures. A spatially selective Hadamard
NMR experiment (Murali et al., 2006) was used to simultaneously
acquire a 1D 1H spectrum of compounds in the presence of
DsbB/DPC or OmpA/DPC. The data resulting from the screen
could be analyzed directly without deconvolution because
fragments could be directly identified by comparing peaks
from TINS spectra with reference spectra of the individual frag-
ment (Figure 2). The screen resulted in 93 hits for DsbB, defined
as fragments which had a T/R ratio less than 0.3, as shown by an
example of a mix containing two hits in Figure 2. This particular
cutoff was chosen by virtue of a step-like relationship between
the observed TINS effect and the number of ‘‘hits’’ whereby
even slightly raising the cutoff gave a large increase (>2-fold) in
the number of compounds that were selected as hits (not
shown). The resulting hit rate for DsbB was 8.7% which is well
within the range we typically observe with soluble proteins using
TINS (3%–9.5%). Application of the same criteria to OmpA/DPC
binding identified seven compounds as hits for a hit rate of 0.6%,
validating the earlier data suggesting that OmpA/DPC has
minimal small molecule binding capacity.Comparison of Micelle-Solubilized versus
ND-Solubilized Protein for Ligand Binding Studies
The influence of detergent or ND on the quality of the NMR
spectra of the fragments is shown in Figures 2D and 2E.
In both cases, the compound whose spectrum is shown in
Figure 2C can be identified as specifically binding to DsbB.
However, the signal-to-noise ratio of the compounds (Figures
2A and 2B) in Figure 2E is nearly double that in Figure 2D
(most readily observed on the aromatic resonances, but see
also the peak at 3.1 ppm). The improved quality of the spectra
allows more reliable analysis of the peaks at 7.3 and 7.4 ppm,
which are now clearly seen to indicate specific binding of this
compound to DsbB/ND, consistent with the behavior of the
peaks at 2.8 and 2.2 ppm. The reduced signal in the presence
of detergent-solubilized protein is likely due to nonspecific parti-
oning of 30%–40% of the compounds into the micelle.1–891, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 883
Figure 2. Detection of Ligand Binding to Im-
mobilized DsbB Using TINS
The 1D 1H NMR spectrum of three different frag-
ments in solution (A–C) is shown for reference.
The 1H NMR spectrum of a mix of the three frag-
ments in the presence of DsbB/DPC (red spec-
trum) or OmpA/DPC (blue spectrum) that have
been immobilized on the Sepharose support is
shown in (D). The spectra of the same mix
recorded in the presence of DsbB/ND (green) or
/ND (magenta) is shown in (E). The asterisk indi-
cates the resonance from residual 1H DMSO and
the bracket shows residual sugar 1H resonances
from the Sepharosemedia. The residual H2O reso-
nance at 4.7 ppm has been filtered out.
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affords the possibility to use NDs directly as a generic reference
to account for nonspecific ligand binding to the phospholipid
bilayer and the scaffolding protein. To investigate this, we
screened all 183 compounds for binding to DsbB/ND using
either OmpA/ND or /ND as a reference. By plotting the T/R
for each compound from the screen using /ND versus that of
using OmpA/ND, we derive a 2D plot that gives an overview of
the performance of the screen (Figure 3A). Overall there was
a reasonable correlation in ligand binding to DsbB/ND using
either empty NDs or OmpA/ND as the reference (R2 = 0.78).
In general, however, the T/R ratio of fragments is lower with
/ND as a reference, indicating that specific binding to DsbB/
ND is more pronounced. Since the NMR spectra of the frag-
ments in the presence of DsbB/ND in the screen versus /ND
or OmpA/ND are similar, this suggests a higher level of nonspe-
cific binding of the fragments to OmpA/ND. We conclude there-
fore that /ND is the preferred reference.
We then compared the ligand screening results from DsbB/
DPC (OmpA/DPC as reference) to those from DsbB/ND (/ND
as reference). Upon inspection of the raw NMR data from the
DPC screen, we observed that although 183 compounds were884 Chemistry & Biology 17, 881–891, August 27, 2010 ª2010 Elsevier Ltd All rights reservedpresent in the 40 mixes selected, only
127, about two-thirds, gave observable
NMR spectra. Presumably, those com-
pounds missing from the NMR data had
nonspecifically adsorbed to the micelle.
We compared the calculated Log of theoctonal/water partition coefficient (cLogP) for compounds that
could be observed (median 0.9) and could not be observed
(median 1.8) for evidence to support this assumption. Despite
the inaccuracies of cLogP values, there is a clear trend toward
more hydrophobic compounds in the group of compounds
whose NMR spectra were unobservable in the presence of
micelles. In contrast, 164 of 183 compounds gave observable
spectra in the ND screen. The median cLogP for the observable
compounds was 1.1 and 1.6 for the unobservable. However, the
small size of the set of unobservable compounds in the presence
of ND renders the median cLogP value meaningless. Of the 127
compounds with observable spectra in the DPC screen, 70 were
of sufficiently high quality to allow a reliable comparison with the
ND screen, and we therefore focused our efforts on these.
Inspection of Figure 3B clearly shows that the correlation
between the micelles and NDs is much less pronounced than
between the two ND references. Using the same criteria for hit
selection for both, 22 hits were identified for DsbB/ND and 22
were identified for DsbB/DPC. Of these biophysically detected
hits, 14 were common to both the micelle and ND (red) screen
while 8 were unique to the ND screen (blue) and 8 were unique
to the micelle screen (green, see also Table 1). We analyzedFigure 3. Comparison of TINS Screening in
Micelles versus NDs
A total of 70 fragments were assayed for binding to
DsbB solubilized in either detergent micelle or ND.
(A) The 70 fragments were screened for binding to
DsbB/ND using either empty ND (/ND) or OmpA/
ND as a reference. The T/R (see text) for each
compound is plotted for one screen versus the
other. R2 = 0.78.
(B) The T/R for each compound in the DsbB/ND
versus /ND screen is plotted against the value
from the DsbB/DPC versus OmpA/DPC screen.
Hits common to both screens are show in red.
Hits found only in the ND screen are shown in
blue while those found only in the DPC screen
are in green.
Table 1. Fragment Hits from the Screen of DsbB in Micelles and
NDs
Hits cLogP BioAssay in ND BioAssay in DPC
Micelle 8 1.34  +
ND 8 2.21 ++ ++
Both 14 2.13 ++ ++
Note: , poor correlation between enzyme inhibition and binding assay;
+, reasonable correlation (approximately 50% hits bioactive); ++, good
correlation (80%–90% bioactive); cLogP is the median value.
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Interestingly, the hits specific for the ND screen are on average
slightly more hydrophobic than the hits found in both screens,
but the hits specific to the micelle screen are considerably
more hydrophilic (Table 1). A possible explanation for this obser-
vation is that the more hydrophobic fragments exhibited greater
nonspecific binding to the micelle, thus masking specific binding
to DsbB. This observation is consistent with the NMR data in
Figure 2. Using the same criteria, 2 out of the 183 compounds
assayed bound to /ND (1.1% hit rate). Given the small sample,
this hit rate is similar to that for OmpA/DPC.Hit Validation Using Enzymatic Assays
The TINS assay simply identifies compounds that bind to DsbB,
but not necessarily in a biologically relevant manner. Therefore,
we felt it was critical to validate the hits in terms of biological
activity. We used an enzymatic assay to assess the ability of
the compounds to inhibit electron transfer mediated by DsbB.
Each of the 93 fragments identified as TINS hits in the micelle
screen was assayed for inhibition of DsbB-dependent reoxida-
tion of DsbA at 250 mM (Supplemental Information). Eight
compounds interfered with the assay when run in either fluores-
cence or absorbance mode and therefore were left out of
the analysis. The remaining 85 hits exhibited a distribution of
potencies against DsbB, including 60% with better than 30%
enzymatic inhibition and 16%with either less than 20% inhibition
or stimulation. These data confirm that a very high percentage of
the hits found in the biophysical assay also modulate the enzy-
matic activity of DsbB and are functionally relevant.
We next used the inhibition assay to compare hits selected
in the micelle screen to those selected in the ND screen (see
Table 1). As expected, fragments common to both the micelle
and ND screens yielded a strong correlation with biological
activity with 12/14 exhibitingmedium (30%–70%) or high (>70%)
inhibition of DsbB in bothmicelles andNDs.We observed a good
correlation between ligands detected in the ND screen and
biochemical activity against both micelle and ND-solubilized
DsbB where six of seven compounds had medium inhibitory
activity and the seventh was a mild stimulator. In contrast, while
the micelle-specific ligands correlated reasonably well with the
bioassay using detergent-solubilized DsbB where five of eight
were medium or strong inhibitors, none inhibited DsbB/ND.
To avoid the possibility of artifacts in the biochemical assay,
we selected the 13 fragments from the micelle screen showing
strong inhibition in the single concentration point assay for
further analysis. We first assayed these 13 fragments for potency
(IC50) by dose-response experiments (Figure 4; SupplementalChemistry & Biology 17, 88Information). Dose-response experiments were carried out with
increasing fragment concentrations, from 0.0001 to 10 mM,
while both DsbA and UQ1 were kept in excess. Three of the 13
fragments indeed showed artifacts including signs of protein
precipitation at higher compound concentration and/or steeper
than expected Hill coefficients. The remaining ten fragments
titrated over 2 Log orders and exhibited a Hill coefficient close
to unity. By these criteria, the ten fragments are reversible inhib-
itors with a 1:1 stoichiometry and are therefore well behaved.
The eight most potent compounds had IC50 values between 7
and 170 mM and consisted of a variety of scaffolds (Figure 4).
The calculated binding efficiency index (Abad-Zapatero and
Metz, 2005) (Supplemental Information) indicates that these
fragments are all very good or excellent starting points for hit
elaboration projects.
As a second validation step, we carried out a more detailed
kinetic analysis of the mode of action of the eight most potent
fragments. Substrate-velocity experiments were performed in
which either DsbA or UQ1 were titrated in the presence of satu-
rating amounts of the other. The titrations were then repeated in
the presence of increasing amounts of the inhibitory fragment
(Figure 5; Supplemental Information). In this analysis, fragments
1–3 behaved similarly. This group is exemplified by fragment
2 where increasing concentrations result in moderate perturba-
tion of the maximum enzymatic turn over rate (kcat) and apparent
affinity of DsbA but a dramatic reduction (>6-fold) in the apparent
affinity of UQ1. These data suggest that fragments 1–3 compete
for the same binding site as UQ1. On the other hand, addition of
fragments 4–8 simultaneously decreased both the apparent
affinity and the kcat for UQ1 and DsbA as best exemplified by
fragment 8 (Figure 5; Supplemental Information). These data
suggest a mixedmodel of inhibition of DsbB by these fragments.
We next sought biophysical confirmation of these two different
modes of fragment interaction with DsbB.
Confirmation of Different Modes of Interaction
with DsbB by NMR
Chemical shift perturbations of the protein NMR spectrum (typi-
cally 2D 15N-1H HSQC or 13C-1H HSQC) in the presence of
compounds can both confirm binding to the target and localize
the binding site on a protein when resonance assignments are
available (Shuker et al., 1996). While the sequential assignment
of wild-type DsbB is not available due to the poor quality of the
NMR spectra, spectra of the DsbB[CSSC] double cysteine
mutant are of high quality, resulting in a complete backbone
resonance assignment for this form of the protein (Zhou et al.,
2008). When purified from E. coli, DsbB[CSSC] contains the
endogenous ubiquinone-8 (Bader et al., 1999), thus compounds
specific for this site must compete with UQ8 for binding. We
first titrated the synthetic quinone UQ1 into a sample of 15N
DsbB[CSSC]. Addition of UQ1 to 15N DsbB[CSSC] resulted in
numerous chemical shift perturbations but two in particular
afford a detailed analysis of the binding and allow a reliable
comparison with the fragments found in TINS screening. As
shown in Figure 6, the side-chain indole of Trp135 (in the vicinity
of the quinone binding site) (Supplemental Information) and the
backbone amide of Arg109 (close to the DsbA binding site)
respond very differently to addition of UQ1. Titration of UQ1
resulted in the simultaneous disappearance of the Trp1353-HN1–891, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 885
Figure 4. Potency Determination of
Selected Hits from the TINS Screen
An example of an inhibition curve used to deter-
mine the IC50 for compound 2. The curve repre-
sents the mean ± SEM of three independent
experiments performed in triplicate. The struc-
tures of the eight most potent compounds are
shown as well as the IC50 values. See also Figures
S2 and S3.
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the appearance of a new peak close by in the spectrum. Due
to its proximity and the unique chemical shift of the Trp3 HN886 Chemistry & Biology 17, 881–891, August 27, 2010 ª2010 Elsevier Ltd All rights reservedproton, in combination with the high level
of conservation of this residue, the new
peak is likely from the Trp3 HN proton
of the UQ1 bound DsbB[CSSC]. This
pattern of peak changes is indicative of
slow exchange on the NMR timescale
(e.g., koff <30 Hz Dd in Figure 6A). In
contrast, the backbone amide of Arg109
is essentially unchanged by the addition
of UQ1. Mapping the chemical shift per-
turbations induced by UQ1 onto the
surface of DsbB confirms that UQ1
binds at the UQ8 site (Supplemental
Information).
Addition of all eight fragments to
15N-labeled DsbB[CSSC] resulted in
detectable changes in chemical shifts,suggesting that the fragments selected by TINS screening and
biochemical assays on wild-type protein also bind the cysteine
mutated form. The presence of chemical shift perturbationsFigure 5. Mode of Action Determination for
the Most Potent DsbB Inhibitors
Fragment 2 was assayed in competition with
synthetic UQ1 (A), the electron acceptor, or
DsbA (B) the electron source. Fragment 8 was
assayed in the same manner (C and D, respec-
tively). The kcat and Km (apparent) determined
from the data are shown in the Supplemental
Information in the absence and presence of the
indicated amount of each inhibitor. See also
Table S3 and Figure S4.
Figure 6. NMR Analysis of Fragment Binding to DsbB
The eight most potent fragments were titrated into 15N DsbB[CSSC]. Data for the synthetic quinone UQ1 (A), competitive fragment 2 (B), and the mixed model
fragment 8 (C) are shown. For each of these three compounds, the structure of the compound is shown in the left column and the characteristic peak perturba-
tions in the [15N,1H] HSQC spectrum (green 0 mM fragment, blue 5 mM fragment, and red 10 mM fragment) are shown in the middle (Tryptophan 135 side-chain
indole) and right columns (Arginine 109 backbone amide). See also Figures S5 and S6.
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buried within the micelle (data not shown) suggests that the
fragments are specifically binding to the protein and not nonspe-
cifically partitioning into the micelle. Fragment 2, which compet-
itively inhibited ubiquinone binding, induced chemical shift
perturbations in a variety of amino acids, including W135 and
R109. The pattern of chemical shift perturbations induced by
fragment 2 closely resembles that induced byUQ1. First, titration
of 2 into 15N DsbB[CSSC] resulted in chemical shift changes
in the W1353-HN peak that were similar to those induced by
UQ1 (i.e., slow exchange). Moreover, the resonance frequency
of the new peak tentatively assigned to the DsbB[CSSC]-2 com-
plex is similar to that of the DsbB[CSSC]-UQ1 complex. Simi-
larly, R109HN, which is minimally affected by UQ1, undergoesChemistry & Biology 17, 88only minor chemical shift perturbations in the presence of 2.
Mapping the chemical shift perturbations induced by 2 onto
the surface of DsbB confirms that binding is similar to UQ1
(Supplemental Information). While 1 and 3 induce chemical shift
perturbations in the spectrum of DsbB[CSSC], the characteristic
ones observed at R109 and W135 are not seen, so the grouping
of these compounds with 2 as UQ8 competitors is tentative,
relying only on the kinetic data.
In contrast, the chemical shift changes induced by fragments
4–8 differ in both the overall pattern and the details from frag-
ment 2 and UQ1 (Figure 6C; Supplemental Information). Addition
of 8, for example, induced concentration dependent shifts in the
Trp1353-HN resonance to an entirely different chemical shift
than did fragment 2 or UQ1. This concentration dependent shift1–891, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 887
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no evidence for slow exchange for any of the fragments 4–8,
although 4 and 7 show signs of line broadening of the backbone
resonance of Q33 that may indicate intermediate exchange (not
shown). In contrast, the backbone amide of R109, which is only
mildly perturbed by UQ1 or 2, is very dramatically perturbed by
the addition of fragment 8. These data suggest that fragments
4–8, which exhibit mixed mode DsbB inhibition, bind in either
a different mode or different site to fragment 2 which is compet-
itive with ubiquinone.
DISCUSSION
The use of Ro3-compliant, ‘‘drug fragments’’ as a starting point
for drug discovery has delivered a number of innovative com-
pounds against soluble targets which are currently in clinical
trials (Hajduk and Greer, 2007). Membrane proteins have not
made good targets for FBDD due to their challenging physico-
chemical properties. In particular, the difficulty of generating
sufficient quantities of purified, functional protein and of detect-
ing specific binding to the target, as opposed to nonspecific
partitioning into hydrophobic phases, has limited the applica-
bility of biophysical ligand screening approaches. Here, we
have addressed these two issues by (a) immobilizing the target
and reusing a single sample to screen an entire fragment collec-
tion and (b) using a reference sample to cancel out nonspecific
interaction of the fragments with the hydrophobic phase. Using
TINS we have screened a collection of nearly 1100 fragments
with a single sample of less than 2 mg of protein and demon-
strated that the protein was stable throughout the procedure.
The stability of DsbB to repeated cycles of fragment application
and washing depends on detergent micelles and the quinone
cofactor. The detergent requirement could be overcome by
including it in the buffer or using NDs to solubilize the protein.
Endogenous UQ8 binds DsbB very tightly and is quite resistant
to repeated detergent washing (Inaba et al., 2004).
Screening of the fragment library resulted in 93 ligands that
were specific for DsbB. A number of observations suggest that
most of these ligands are directly binding to DsbB and not indi-
rectly via the micelle. First, the DsbB binding detected using
TINS was relative to OmpA solubilized in identical conditions.
Second, there is a range of potencies in the enzyme inhibition
studies that includes a small number of noninhibitors and activa-
tors. Third, and perhaps more critically, inhibition is saturable
and occurs over 2 log orders, strongly suggesting a stoichio-
metric interaction. Fourth, titration of eight different fragments
into 15N-labeled DsbB resulted in chemical shift perturbations
at well-defined sites in both solvent exposed and micelle buried
portions of the protein. In particular, the similarity of the chemical
shift perturbations induced by the synthetic quinone UQ1 and
fragment 2 indicates the compounds are binding to the same
or overlapping sites. An additional, likely important, factor con-
tributing to the low false positive rate is that the fragments that
make up the collection are highly soluble, with each having
been tested at 500 mM in an aqueous buffer alone and in
a mixture. Nonetheless, an appreciable fraction of these frag-
ments exhibit sufficient nonspecific binding to the micelle that
they were only poorly or even not detected in the NMR spectra.
These data suggest that ligand screening in the presence of888 Chemistry & Biology 17, 881–891, August 27, 2010 ª2010 Elsevimicelle-solubilized membrane proteins may bias the chemical
nature of the fragment library. The median cLogP for observable
compounds in the presence of ND-solubilized proteins is slightly
greater (0.9 versus 1.1) suggesting a reduced tendency of hydro-
phobic compounds to partition into the nanodisc.
The eight fragments with greatest potency in the single
concentration enzyme inhibition assay were fully characterized
for potency, mode of action, and binding site on DsbB. A sim-
plistic analysis suggests that these fragments can be divided
into two groups, one that competes only with quinone for
DsbB binding and a second that perturbs the apparent affinity
of DsbB for both quinone and DsbA. The different mode of action
is best exhibited by the differing effect on the apparent Km for
UQ1 or DsbA for each. Addition of fragment 2 reduced Km for
UQ1 more than 8-fold, while it had only a marginal effect on
the Km for DsbA (only 5% greater than experimental error). In
contrast, addition of 8 reduced Km for UQ1 more than 4.4-fold
and Km for DsbA more than 2-fold.
The different behavior of the resonances of the backbone
amide of R109 and the side-chain indole of W135 upon titration
with the fragments provides further support for two modes of
action. Titration of UQ1 DsbB[CSSC] results in slow exchange
between the endogenous quinone bound form and a newly
arising peak at a nearby position which we assign to the UQ1
complex. Similarly, addition of 2 resulted in slow exchange
between the endogenous quinone bound form of W1353 NH
and the appearance of a new peak with similar chemical shift
as the UQ1 complex. An additional chemical shift perturbation
indicating fast exchange with the endogenous complex was
also observed. The fast exchange is likely due to competition
between 2 and the quinone moiety of the bound UQ8, consistent
with the competitive kinetics observed for this inhibitor.
However, we have shown that the isoprenyl tail of UQ8 extends
down the groove between TM1 and TM4, making extensive
interactions with the protein (Zhou et al., 2008). Therefore,
displacement of the isoprenyl moiety apparently occurs on a
slower timescale. Addition of 8 to DsbB[CSSC] also causes
chemical shift perturbation of the W1353 NH but these suggest
rapid exchange between a typical 2-state equilibrium rather
than the more complex effects seen with 2. In addition, the
bound state has a different resonance frequency than the bound
state of UQ1 or 2. Additional large downfield chemicals shifts of
the resonance of R109N, indicative of rapid exchange, are
observed while UQ1 and 2 had no or only minor effects on this
peak. From a drug discovery perspective, these data are exciting
because it suggests, as with soluble enzymes, it is possible to
find small molecule inhibitors with different modes of action
and possibly nonoverlapping or even different binding sites on
membrane proteins.
We note that the concentration of the fragments required to
induce chemical shift perturbations in DsbB[CSSC] is signifi-
cantly higher than the IC50 values measured for the wild-type
protein but the same as required for UQ1. A likely explanation
is that the conformation of the mutant differs slightly from the
wild-type protein, against which the fragments were selected.
In addition, either the affinity for the quinone is higher for the
DsbB[CSSC] mutant or, more likely, the quinone binding site
may be partially occluded. This latter possibility is clearly consis-
tent with the reduced dynamic behavior of DsbB[CSSC] wither Ltd All rights reserved
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improvement in the quality of the NMR spectra. This reduced
dynamic behavior of the disulfide mutant may be responsible
for the slow exchange kinetics observed for UQ1 and 2 if release
of the UQ8 from this binding site can only occur from a sparsely
populated conformation.
Functional solubilization of membrane proteins in detergent
micelles is a challenging process that must be individually opti-
mized for each protein. NDs offer the potential to enable
a more generic approach to handling membrane proteins since
they can be used to functionally solubilize a variety of mem-
brane proteins and can obviate the requirement for an interme-
diate micelle-solubilized step (Katzen et al., 2008; Civjan et al.,
2003). Furthermore, immobilization can be made generic for
all MPs with minimal effect on functionality by appropriate
engineering of the MSP portion of the ND. Use of NDs as a
generic solubilization/immobilization system for ligand screening
is further enabled by the stability of the empty ND and the
fact that it represents a high-quality reference system to remove
false positives. This conclusion is strongly supported by the
observation that the eight DsbB/DPC-specific hits failed to
inhibit DsbB/ND while seven of eight DsbB/ND hits also inhibited
DsbB/DPC. Apparently, despite the reference sample, some
compounds interact with DsbB in a micelle-specific manner.
This problem would be largely eliminated by using NDs.SIGNIFICANCE
Integral membrane proteins make up a significant portion
of the human genome, carrying out numerous important
normal as well as disease-related functions. More than
50% of drugs currently on the market target a membrane
protein, demonstrating the utility of targeting this class of
proteins. Approaches for the development of drugs target-
ing this class of proteins have focused principally on the
use of high-throughput screening methods. Recently, frag-
ment-baseddrugdiscovery (FBDD)hasemergedasapower-
ful additional drug discovery approach. Because of the typi-
cally modest binding affinities of the small, functional group
rich, i.e., high ligand efficiency, compounds utilized in FBDD,
various biophysical techniques, including NMR, are typically
used to detect binding. To date, several compounds devel-
oped using FBDD have advanced to clinical trials (Hajduk
and Greer, 2007). However, thus far FBDD has been demon-
strated only for soluble proteins, not membrane proteins.
Herein, we describe the first complete screen of a frag-
ment collection against an integral membrane protein. The
screen was performed using a detergent micelle-solubilized
protein using a simple and rapid 1D NMR method we
described previously (TINS). The 93 hits were subsequently
validated in an enzyme inhibition study. The use of a refer-
ence sample in the TINS experiment eliminated the well-
documented problem of nonspecific binding of compounds
to the detergent. As membrane protein activity is enhanced
in more bilayer-like environments, we have also solubilized
the protein in NDs and shown that the screening approach
is effective with this preparation as well. The use of NDs
further ameliorates issues with nonspecific binding andChemistry & Biology 17, 88should also extend the method to proteins which typically
do not behave well in detergents such as GPCRs.
Our results clearly establish the feasibility of using a frag-
ment-based approach for finding starting matter for subse-
quent development of compounds targeting membrane
proteins, including the all-important GPCR class of proteins.
In addition, increasing success in the preparation of mem-
brane proteins in reasonable quantities should make many
such proteins amenable to the use of TINS for fragment
screening, thereby increasing its general utility.
EXPERIMENTAL PROCEDURES
Protein Purification
DsbA, DsbB, and OmpA were expressed and purified as previously reported
(Bader et al., 1999, 2000; Arora et al., 2000). All proteins have a 6x-His tag at
the N terminus or C terminus for affinity purification. Successful refolding of
OmpA from inclusion bodies was monitored by SDS-PAGE analysis (Arora
et al., 2000).
ND Self-Assembly
The ND self assembly procedure was repeated the same way for both OmpA
and DsbB with slight adaptations from the previously reported procedures
(Civjan et al., 2003). The reconstitution mixture contained Membrane Scaffold
Protein MSP1D1() which lacked the His tag, with mixed micelles of POPC
and cholate at a ratio of 1:65:130. This reconstitution mixture was added to
the OmpA or DsbB in detergent micelles (each with 103 the detergent CMC)
in a volumetric ratio of 1:1 and incubated on ice for 4 hr. We always ensured
a stoichiometry of MSP1D1() to OmpA or DsbB of 2:1. Upon addition of
0.7 g/ml of the hydrophobic adsorbent Bio-Beads SM-2 (Biorad, Hercules,
CA) and gently mixing for 4 hr at 4C, the NDs underwent self-assembly, incor-
porating DsbB or OmpA in the lipid bilayer. This step was limiting, whereby
detergent removal before 4 hr resulted in incomplete ND formation, but caused
ND complex malformation if carried out for longer (i.e., 16 hr, data not shown).
The His tag of the embeddedOmpA andDsbBwas used to separate the empty
nontaggedMSP1D1() complexes from themixture by IMAC chromatography
using Ni-NTA resin in a buffer containing 100 mM Tris-HCl (pH 7.5), 300 mM
NaCl, and imidazole at 0, 10, and 100 mM for loading, washing, and elution,
respectively. The eluted fractions were applied to a gel filtration column
(Superdex 200 10/300 from GE Healthcare) in order to remove the remaining
aggregated, nonembedded OmpA and DsbB, and to exchange the ND-
embedded proteins into phosphate buffered saline (PBS, pH 7.4) for compat-
ibility with the immobilization step required for TINS. A set of standard proteins
was used to calibrate the Stokes’ diameter versus the retention time of the
column.
Protein Immobilization
Actigel ALD resin (Sterogene, Carlsbad, CA) was used as a 50% slurry and all
experiments were carried out at 4C when possible. The resin was washed
with cold phosphate buffer (50 mM Na2HPO4, 50 mM KH2HPO4, 100 mM
NaCl [pH 7.5]). Two hundred nanomoles of DPC-solubilized DsbB was added
to 1 ml bed volume of resin. The reductant sodium cyanoborohydride
(NaCNBH3) was added to a final concentration of 0.1 M. After an overnight
incubation at 4C, residual unreacted aldehydes were blocked by addition of
50 mM D11-Tris and fresh NaCNBH3 in the same buffer for another 2 hr. The
same procedure was repeated for DPC-solubilized OmpA. Quantification of
immobilized protein was monitored by absorption of the supernatant at
280 nm before and after immobilization, and by SDS-page gel with a known
standard curve and band volume analysis. These data indicated that a final
concentration of 100 mM of both immobilized DsbB and OmpA was achieved,
equating to a 50% yield. The procedure was repeated identically to immobilize
DsbB and OmpA solubilized in ND (after pooling fractions containing particles
ranging between 9.2 and 9.7 nm) and empty ND at a similar final concentration
as the micelle-solubilized protein. ND preparations could not be quantified by
UV absorption; therefore, they were loaded on SDS-page gels with a BSA
standard curve for band volume quantification by Quantity One (Biorad),1–891, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 889
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incorporated proteins. The yield of immobilized, ND-solubilized protein
was 75%.DsbB Activity Assays
DsbB activity was quantified by measuring the capacity of the enzyme to
reoxidize the protein DsbA or reduce its cofactor ubiquinone-5, also called
coenzyme Q1 (UQ1) (pH 6.2). DsbA was reduced with 10 mM DTT for
10 min on ice. DTT was subsequently removed by gel filtration on a PD-10
column pre-equilibrated with degassed, distilled water containing 0.1 mM
EDTA. DsbA fluorescence (excitation at 295 nm and emission at 330 nm)
wasmeasured in the presence of DsbB and UQ1 in 50mM sodium phosphate,
100 mMNaCl, 0.1% detergent [DPC or DDM depending on which was used to
solubilize DsbB], and 0.1 mM EDTA) at 30C. Both UQ1 and DsbA were added
at final concentrations of 30 mM. DsbB was added at a final concentration of
20 nM. The activity of DsbB in terms of moles ubiquinone reduced/moles
DsbB min-1 could be calculated by using the initial slope of the fluorescence
decrease upon DsbA oxidation, or by using the slope of absorption decrease
at 275 nm upon reduction of UQ1 (Bader et al., 1999).
To measure activity of immobilized DPC- or ND-solubilized DsbB, resin was
aliquoted and diluted with degassed activity assay buffer to a final protein
concentration of approximately 20 nM. For an appropriate baseline, an equiv-
alent amount of resin without protein (blank resin) was prepared in the same
manner. Quinone reduction was monitored in DPC samples after addition of
20 mM coenzyme Q1 and 20 mM DsbA and DsbA oxidation was measured
for ND-solubilized DsbB.Target Immobilized NMR Screening
Immobilized, DPC-solubilized DsbB andOmpAwere each packed into a sepa-
rate cell of a dual-cell sample holder (Marquardsen et al., 2006). Mixes of the
1071 fragments were made by 200-fold dilution of a 100 mM stock of each
compound in d6-DMSO such that the final DMSO concentration was never
greater than 5%. Upon injection of each mix into the dual-cell sample holder,
flow was stopped and spatially selective Hadamard spectroscopy (Murali
et al., 2006) was used to acquire a 1D 1H spectrum of each sample separately.
A CPMGT2 filter of 80mswas used to remove residual broad resonances from
the Sepharose resin. The cycle time was about 35min, with 30min required for
the NMR experiment and 5 min for sample handling, resulting in a total time of
about 5.5 days to complete the screen. To maintain the proper fold of each
protein, 5 mM deuterated DPC was included in the buffer (20 mM phosphate
buffer in D2O, 100 mM NaCl [pH 7.6]) used to wash the fragment mixes from
the sample holder.
Biochemical Hit Validation
All fragments from the screen that were designated as positive for binding
were assayed for DsbB inhibition at 250 mM. The amount of DMSO in all
biochemical assay controls was adjusted to match the amount present
when fragments were tested. Those compounds that showed more than
70% inhibition at 250 mM were further characterized by titration from 0.0001
to 10mM to generate IC50 curves. Themode of action for the eight most potent
fragments was determined from competition enzyme assays. For this analysis
either DsbA or UQ1 was titrated in from 0.2 to 40 mM, while the other was kept
constant at 40 mM. For each titration point, slopes were measured in the pres-
ence of 5, 10, and 75 mM of the fragment. DsbB activity data were analyzed
using the nonlinear regression curve fitting routines in Graph Pad Prism v. 5.01
(Graph Pad, San Diego, CA). Statistical significance was evaluated with the
Student’s t test. Depending on the light absorbing properties of the fragments,
they were used in either the fluorescence or UV-absorbance assay.
Compounds which were not compatible with the assays due to high intrinsic
fluorescence, high UV absorbance, or irregular baselines were not included
in the analysis.
Biophysical Hit Validation
Due to the poor quality of the NMR spectra of the wild-type DsbB, it was
necessary to use a mutant that represents an intermediate in the disulfide
oxidation pathway (Zhou et al., 2008). Validated hits from the screen were
titrated at 1, 5, and 10 mM into 15N-labeled DsbB[CSSC] mutant (C44S,
C104S). [15N,1H] HSQC experiments were acquired at 40C in a Bruker DRX
600 MHz spectrometer equipped with a cryoprobe. A reference titration of890 Chemistry & Biology 17, 881–891, August 27, 2010 ª2010 ElseviDMSO and a nonbinding fragment from the screen were used to subtract
chemical shift perturbations not related to fragment binding.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and three tables and can be
found with this article online at doi:10.1016/j.chembiol.2010.06.011.
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